Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KVAC Stock Forecast 2025-2026
$11.32
Current Price
$122.49M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KVAC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
KVAC Price Momentum
+0.6%
1 Week Change
0.0%
1 Month Change
+7.2%
1 Year Change
+3.1%
Year-to-Date Change
-0.3%
From 52W High of $11.35
+7.2%
From 52W Low of $10.56
📊 TOP ANALYST CALLS
Did KVAC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Keen Vision is one of their latest high-conviction picks.
Latest KVAC Stock Price Targets & Analyst Predictions
KVAC has shown a year-to-date change of 3.1% and a 1-year change of 7.2%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for KVAC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KVAC Analyst Ratings
0
Buy
0
Hold
0
Sell
KVAC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $11.32
Latest KVAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KVAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Keen Vision Acquisition Corp. (KVAC) Competitors
The following stocks are similar to Keen Vision based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Keen Vision Acquisition Corp. (KVAC) Financial Data
Keen Vision Acquisition Corp. has a market capitalization of $122.49M with a P/E ratio of 14.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +11.2%.
Valuation Metrics
Market Cap
$122.49M
Enterprise Value
$123.67M
P/E Ratio
14.9x
PEG Ratio
-0.1x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
-82.6%
Financial Health
Cash/Price Ratio
+0.0%
Current Ratio
0.0x
Debt/Equity
0.0x
ROE
+11.2%
ROA
+10.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Keen Vision Acquisition Corp. (KVAC) Business Model
About Keen Vision Acquisition Corp.
What They Do
Facilitates mergers and acquisitions for companies.
Business Model
The company operates as a special purpose acquisition company (SPAC), raising substantial capital to merge with or acquire promising businesses that seek to enter public markets. It generates value by streamlining the process for these companies, allowing them to access public funding and resources more efficiently than traditional IPO routes.
Additional Information
Keen Vision Acquisition Corp. targets sectors with rapid technological advancements and strong growth potential, providing essential support for emerging companies. Its strategic partnerships and expertise in navigating regulatory complexities enhance its effectiveness in bridging private enterprises with public markets.
Company Information
Sector
Financial Services
Industry
Shell Companies
Employees
0
CEO
Mr. Ka Chun Wong
Country
United States
IPO Year
2023
Website
www.kv-ac.comKeen Vision Acquisition Corp. (KVAC) Latest News & Analysis
Latest News
Quick Summary
Medera Inc. presented seven scientific abstracts at the ISSCR Annual Meeting in Hong Kong, highlighting advancements in cardiovascular therapeutics and cardiac tissue engineering.
Why It Matters
Successful presentation of scientific abstracts enhances Medera's credibility and visibility in the biopharmaceutical sector, potentially attracting investment and partnerships.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
1 month ago
Quick Summary
Medera Inc. will present Phase 1/2a trial data on its gene therapy candidate SRD-002 for heart failure with preserved ejection fraction at the Heart Failure 2025 Congress from May 17-20.
Why It Matters
The presentation of SRD-002 trial data at a major congress could significantly impact Medera’s stock price and investor sentiment, especially if results indicate strong efficacy or safety.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Medera Inc. presented updated results from its MUSIC-HFpEF Phase 1/2a trial for SRD-002, a gene therapy for cardiovascular diseases, at the HFpEF Summit in March 2025.
Why It Matters
Medera's positive trial results for SRD-002 could indicate breakthroughs in treating cardiovascular diseases, potentially boosting stock value and attracting investment in innovative biopharma solutions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Medera Inc. announced that the Data and Safety Monitoring Board has recommended proceeding to Phase 2 of the MUSIC-HFrEF trial for its gene therapy SRD-001 in heart failure patients.
Why It Matters
Medera's positive trial progress for its gene therapy SRD-001 indicates potential future revenue and market position in cardiovascular treatments, impacting investor sentiment and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Medera Inc. completed patient dosing in its MUSIC-HFrEF Phase 1/2a trial for gene therapy candidate SRD-001, targeting heart failure with reduced ejection fraction.
Why It Matters
Completion of patient dosing in Medera's trial for SRD-001 could signal progress in treating heart failure, potentially leading to market opportunities and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Medera's Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht
4 months ago
Quick Summary
Novoheart's CTScreen™ system has been installed at UMC Utrecht, enhancing cardiac disease modeling and therapy development, potentially leading to new co-development projects.
Why It Matters
Novoheart's CTScreen™ installation at UMC Utrecht enhances cardiac research capabilities, potentially leading to breakthroughs in therapies, which could boost Medera's valuation and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About KVAC Stock
What is Keen Vision Acquisition Corp.'s (KVAC) stock forecast for 2025?
Analyst forecasts for Keen Vision Acquisition Corp. (KVAC) are not currently available. The stock is trading at $11.32.
Is KVAC stock a good investment in 2025?
Analyst ratings for KVAC are not currently available. The stock is currently trading at $11.32. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KVAC stock?
Price predictions from Wall Street analysts for KVAC are not currently available. The stock is trading at $11.32.
What is Keen Vision Acquisition Corp.'s business model?
The company operates as a special purpose acquisition company (SPAC), raising substantial capital to merge with or acquire promising businesses that seek to enter public markets. It generates value by streamlining the process for these companies, allowing them to access public funding and resources more efficiently than traditional IPO routes.
What is the highest forecasted price for KVAC Keen Vision Acquisition Corp.?
Price targets from Wall Street analysts for KVAC are not currently available. The stock is trading at $11.32.
What is the lowest forecasted price for KVAC Keen Vision Acquisition Corp.?
Price targets from Wall Street analysts for KVAC are not currently available. The stock is trading at $11.32.
What is the overall KVAC consensus from analysts for Keen Vision Acquisition Corp.?
Analyst ratings for KVAC are not currently available. The stock is trading at $11.32.
How accurate are KVAC stock price projections?
Stock price projections, including those for Keen Vision Acquisition Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 11:43 PM UTC